Compare Live Nation Entertainment, Inc. (LYV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Live Nation Entertainment, Inc. trades at $169.98 (market cap $39.33B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Live Nation Entertainment, Inc. is far larger — about 5.4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is more actively traded (1,624,631 versus 1,350,559). Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LYV | SYRE | |
|---|---|---|
Market Cap | $39.33B | $7.35B |
Volume | 1,350,559 | 1,624,631 |
Sector | Media | Health |
52-Week High | $188.46 | $108.92 |
52-Week Low | $125.61 | $22.18 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $41.54B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $171.32, up 0.99% today, with a neutral technical signal and strong analyst support. The stock shows robust revenue growth, reaching $25.20B in 2025, but profitability remains thin with a net margin of 0.51% and a high P/E of 117.49. Recent news highlights strong fan demand and strategic partnerships, such as the Salesforce integration announced on September 16, 2026, while legal and debt risks persist.
The outlook is cautiously optimistic, driven by sustained demand for live events and a consensus price target of $208.64, but investors face risks from high valuation, regulatory scrutiny, and volatile earnings, with Q3 2026 results critical for confirming growth momentum.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
